Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II

Saved in:

Bibliographic Details
Main Authors:	Junjiang Fu, Luca Antonioli, Xiaoli Zheng, Ali H. El-Far
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	adenosine cancer immunity cancer immunotherapy adenosine signaling immunotherapy immune checkpoint inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1538930/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Altered CD73-Adenosine Signaling Linked to Infection in Patients undergoing hemodialysis
by: Xiang F, et al.
Published: (2025-01-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy
by: Nan Zhang, et al.
Published: (2025-02-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
by: Man Wang, et al.
Published: (2025-01-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01)

Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01)

Immunotherapy in Recurrent Ovarian Cancer
by: Keyao Chen, et al.
Published: (2025-01-01)

Overcoming immune evasion with innovative multi-target approaches for glioblastoma
by: Hai Su, et al.
Published: (2025-01-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

Neoantigen mRNA vaccines and A2A receptor antagonism: A strategy to enhance T cell immunity
by: Saber Imani, et al.
Published: (2025-12-01)

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
by: Renate Pichler, et al.
Published: (2024-12-01)

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
by: Anqi Lin, et al.
Published: (2025-12-01)

Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
by: Javier García-Corbacho, et al.
Published: (2025-02-01)

The success of the tumor immunotherapy: neutrophils from bench to beside
by: Meng Zhu, et al.
Published: (2025-01-01)

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings
by: Maria Meira, et al.
Published: (2024-12-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer
by: Andry Santoso, et al.
Published: (2024-12-01)

A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response
by: Bing Feng, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies
by: Li-Chun Lu, et al.
Published: (2023-04-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies
by: Reza Panahizadeh, et al.
Published: (2025-01-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
by: Zongfu Pan, et al.
Published: (2025-02-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
by: Konstantinos Lallas, et al.
Published: (2025-01-01)

An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers
by: Ruyi Liu, et al.
Published: (2025-02-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy
by: Manqing Peng, et al.
Published: (2024-12-01)

Profile of STING agonist and inhibitor research: a bibliometric analysis
by: Xuemei Wang, et al.
Published: (2025-02-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II–IVa esophageal cancer: a network meta-analysis
by: Mingxing Wang, et al.
Published: (2025-01-01)